{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:44:14Z","timestamp":1791081854518,"version":"4.1.0"},"reference-count":62,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T00:00:00Z","timestamp":1409184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:p>\n                    Dual antiplatelet therapy, composed of aspirin plus a\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    \u2010receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (\n                    <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content>\n                    ). A number of U.S. Food and Drug Administration\u2013approved\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    \u2010receptor antagonists are available for treating patients with\n                    <jats:styled-content style=\"fixed-case\">ACS<\/jats:styled-content>\n                    , including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct\u2010acting\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    \u2010receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In pharmacodynamic studies, ticagrelor demonstrated faster onset and more potent inhibition of platelet aggregation than clopidogrel. These properties of ticagrelor may contribute to reduced rates of thrombotic outcomes compared with clopidogrel, as demonstrated in a phase\n                    <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                    clinical trial. However, in addition to bleeding, distinctive adverse effects of this new chemical entity have not been reported with the thienopyridine\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    \u2010receptor inhibitors. Although ticagrelor represents an advancement in\n                    <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                    2\n                    <jats:styled-content style=\"fixed-case\">Y<\/jats:styled-content>\n                    <jats:sub>12<\/jats:sub>\n                    \u2010receptor inhibition therapy, a thorough understanding of this compound as an antiplatelet therapy remains to be elucidated.\n                  <\/jats:p>","DOI":"10.1002\/phar.1477","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T04:38:39Z","timestamp":1409200719000},"page":"1077-1090","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":211,"title":["Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety"],"prefix":"10.1002","volume":"34","author":[{"given":"Paul P.","family":"Dobesh","sequence":"first","affiliation":[{"name":"College of Pharmacy University of Nebraska Medical Center Omaha Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie H.","family":"Oestreich","sequence":"additional","affiliation":[{"name":"College of Pharmacy University of Nebraska Medical Center Omaha Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,8,28]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31828124ad"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318256f1e0"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31823ba622"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.827781"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.113.000109"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.9.1089"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2009.00096.x"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.06.029"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm981072s"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.07.057"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03669.x"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.06.023"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.032250"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12026"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.550573"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.037143"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0778-5"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599830-000000000-00000"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.058"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011415526"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010379409"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.092"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1227-4"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.053"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.912550"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.919456"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198308183090703"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248411410883"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.032"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3527"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62191-7"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927582"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.029"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.047498"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110814"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02208.x"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03943.x"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.023"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61088-4"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.720972"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.062"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr231"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.781502"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.11.056"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112053252306"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248413511693"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/21556660.2013.785413"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1436-x"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1543-3"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1369-4"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0205-2"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.666524"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.110.958561"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61274-3"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/09537100903075324"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)90158-1"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1477","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.1477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:27Z","timestamp":1761040827000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,28]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1002\/phar.1477"],"URL":"https:\/\/doi.org\/10.1002\/phar.1477","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,28]]},"assertion":[{"value":"2014-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}